Loading clinical trials...

Azilect® In Wearing-Off (AIWO) | Clinical Trials | Clareo Health

COMPLETED

Azilect® In Wearing-Off (AIWO)

Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)

NCT02384512•Teva Pharma GmbH

View on ClinicalTrials.gov

Summary

End-of-dose fluctuations e. g. wearing-off are defined as a recurrence of motor and non-motor Parkinson's Disease (PD) symptoms that precedes a scheduled dose and improves with the next dose of anti-parkinsonian medication. Azilect® is approved and recommended for therapy of wearing-off-/End-of-dose fluctuations and improves motor fluctuations significantly in combination therapy with L-dopa and other parkinsonian medication.

Detailed Description

The aim of the non-interventional study is to document efficacy and tolerability of rasagiline as a combination therapy in patients with wearing-off-/End-of-dose fluctuations and the effect of rasagiline on individual wearing-off symptoms, recognized by wearing-off questionnaire 32 (WOQ-32).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Inclusion:
•idiopathic Parkinson's disease based on the UK Brain Bank criteria,
•Wearing-off / end-of-dose akinesia
•at least 18 years old,
•written consent to participate in the study.
•Exclusion:
•contraindications according to the SmPC of Azilect®,
•treatment with Azilect® in the past 3 months and / or
•suffering from a relevant cognitive impairment and therefore neither understand the patient information, nor can give their consent to participate.

Locations (140)

Teva Investigational Sites

Aalen, Germany

Teva Investigational Sites

Achim, Germany

Teva Investigational Sites

Altenburg, Germany

Teva Investigational Sites

Altenholz, Germany

Teva Investigational Sites

Alzenau in Unterfranken, Germany

Teva Investigational Sites

Apolda, Germany

Teva Investigational Sites

Aschaffenburg, Germany

Teva Investigational Sites

Bad Honnef, Germany

Teva Investigational Sites

Bad Kissingen, Germany

Teva Investigational Sites

Bad Mergentheim, Germany

Key Dates

Start Date

January 1, 2014

Primary Completion Date

December 1, 2014

Completion Date

January 1, 2015

Last Updated

April 12, 2023

Enrollment

261

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

Azilect®

DRUG

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Azilect® In Wearing-Off (AIWO)

Inclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations